TABLE 1.
Baseline characteristics.
| Characteristic | All patients, N = 35 |
|---|---|
| Age, years (IQR) | 37.4 (23–50) |
| Female sex, n (%) | 8 (23) |
| Height, cm (IQR) | 170.7 (168–179) |
| Weight, kg (IQR) | 70.7 (57.5–85) |
| BMI, kg/m2 (IQR) | 23.9 (20.6–27.7) |
| Heart rate, bpm (IQR) | 71 (59.5–78) |
| Systolic pressure, mmHG (IQR) | 106 (100–114) |
| Diastolic pressure, mmHG (IQR) | 69 (60–75) |
| Follow‐up, months (IQR) | 6.6 (6–7) |
| Laboratory | |
| hs‐cTnT 0 h, ng/L (IQR) | 34.4 (17.5–46.2) |
| hs‐cTnT 0 h ≥ 14 ng/L, n (%) | 33 (94.3) |
| hs‐cTnT 1 h, ng/L (IQR) | 32.3 (17.2–42.9) |
| hs‐cTnT 1 h ≥ 14 ng/L, n (%) | 34 (97.1) |
| hs‐cTnT FU, ng/L (IQR) | 34.3 (16.8–43.9) |
| hs‐cTnT FU > 14 ng/L, n (%) | 33 (94.3) |
| hs‐cTnI 0 h, ng/L (IQR) | 20 (6–43) |
| hs‐cTnI 1 h, ng/L (IQR) | 26 (7–41) |
| hs‐cTnI FU, ng/L (IQR) | 17 (6–42) |
| hs‐cTnI 0 h, 1 h, or FU ≥ 45 ng/L, n (%) | 10 (28.6) |
| Creatinine, mg/dL (IQR) | 0.55 (0.18–0.8) |
| eGFR, mL/min/1.73 m2 (IQR) | 158.6 (97.9–211.1) |
| Cystatin C, mg/L (IQR) | 1.1 (0.9–1.17) |
| NT‐proBNP, ng/L (IQR) | 359 (113–605) |
| CK, U/L (IQR) | 501.3 (216.5–754) |
| Myoglobin, μg/L (IQR) | 150 (84.5–190.5) |
| Diagnostic workup | |
| TTE LVEF, % (IQR) | 45 (35–54.3) |
| TTE LVEF < 52%, n (%) | 24 (69) |
| Diastolic dysfunction grade II, n (%) | 11 (31.4) |
| Diastolic dysfunction grade III, n (%) | 6 (17.1) |
| Conduction disorders, n (%) | 11 (31.4) |
| cMRI LVEF, % (IQR) | 49.2 (40–60) [n = 19] |
| Cardiac involvement, n (%) | 34 (97.1) |
| Lung involvement, n (%) | 10 (29) |
| Atrial fibrillation, n (%) | 5 (14) |
| Atrial flutter, n (%) | 3 (8.5) |
| Hypertension, n (%) | 5 (14) |
| Hypercholesterolemia, n (%) | 5 (14) |
| ICD, n (%) | 2 (5.7) |
| Pacemaker, n (%) | 2 (5.7) |
| Chronic kidney disease, n (%) | 5 (14) |
| Medication distribution, n (%) | |
| ASS | 3 (8.5) |
| NOAC | 6 (17) |
| Phenprocoumon | 1 (2.8) |
| ACE inhibitors | 24 (68.6) |
| Sacubitril/valsartan | 6 (17) |
| Beta‐blockers | 28 (80) |
| ARB | 11 (31.4) |
| Diuretics | 8 (22.9) |
| SGLT2 inhibitors | 11 (31.4) |
Abbreviations: ACE, angiotensin‐converting enzyme; ARB, angiotensin receptor blockers; ASS, acetylsalicylic acid; BMI, body mass index; bpm, beats per minute; CK, creatine kinase; cMRT, cardiac magnetic resonance imaging; eGFR, estimated glomerular filtration rate; FU, follow‐up; hs‐cTnI, high‐sensitivity cardiac troponin I; hs‐cTnT, high‐sensitivity cardiac troponin T; ICD, implantable cardioverter‐defibrillator; IQR, interquartile range; LVEF, left ventricular ejection fraction; NOAC, non‐vitamin K antagonist anticoagulant; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; SGLT2; sodium–glucose cotransporter‐2; TTE, transthoracic echocardiography.